OVCON-35 Drug Patent Profile

« Back to Dashboard

When do Ovcon-35 patents expire, and what generic alternatives are available?

Ovcon-35 is a drug marketed by Warner Chilcott and Warner Chilcott Llc and is included in two NDAs.

The generic ingredient in OVCON-35 is ethinyl estradiol; norethindrone. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.

Summary for OVCON-35

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	223
DailyMed Link:	OVCON-35 at DailyMed

US Patents and Regulatory Information for OVCON-35

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Warner Chilcott	OVCON-35	ethinyl estradiol; norethindrone	TABLET;ORAL-21	018127-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Warner Chilcott Llc	OVCON-35	ethinyl estradiol; norethindrone	TABLET;ORAL-28	017716-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

OVCON-35 Market Dynamics, Generic Competition, Patent Status, and Financial Trajectory

Last updated: October 10, 2026

OVCON-35 was a branded chewable oral contraceptive containing norethindrone 0.4 mg and ethinyl estradiol 0.035 mg. Its commercial trajectory followed the standard pattern for an older combination product: initial branded sales, generic substitution, declining strategic value, and eventual brand discontinuation. Current market economics are driven by generic norethindrone/ethinyl estradiol chewable products rather than the OVCON-35 brand.

What was OVCON-35 and who marketed it?

OVCON-35 was a 21-day oral contraceptive tablet indicated for the prevention of pregnancy. The product used a chewable formulation, which differentiated it from conventional swallowable combined oral contraceptives.

Attribute	OVCON-35
Active ingredients	Norethindrone 0.4 mg and ethinyl estradiol 0.035 mg
Dosage form	Chewable tablet
Therapeutic class	Combined hormonal oral contraceptive
FDA pathway	New Drug Application
FDA application	NDA 020685
Original commercial owner	Warner Chilcott
Later corporate ownership	Actavis, followed by Allergan and AbbVie ownership through corporate transactions
Primary market	United States
Current branded status	Discontinued from commercial distribution
Main replacement market	Generic norethindrone/ethinyl estradiol chewable tablets

The product competed in a crowded oral-contraceptive market that included Ortho-Novum, Norinyl, Necon, Femcon Fe, Generess Fe, and numerous generic monophasic and triphasic formulations. OVCON-35's chewable dosage form created some differentiation, but it did not provide durable protection against generic substitution.

When did OVCON-35 lose exclusivity?

OVCON-35's commercial exclusivity ended through the combined effects of patent expiration, generic approvals, and the absence of a durable product-specific barrier. FDA approval of generic equivalents allowed pharmacies and payers to substitute lower-cost products.

The key commercial inflection was the entry of generic norethindrone/ethinyl estradiol chewable tablets. Once an approved generic became available, the brand faced:

• Formulary removal or unfavorable tier placement
• Pharmacy-level substitution
• Lower reimbursement
• Reduced promotional spending
• Declining prescription volume
• Loss of pricing power

For a mature oral contraceptive, the commercial impact of generic entry is usually rapid because the product has no biologic interchangeability barrier and does not require specialty distribution.

What is the FDA and Orange Book status of OVCON-35?

FDA records identify OVCON-35 under NDA 020685 as a norethindrone and ethinyl estradiol oral contraceptive. Public product databases identify the branded product as discontinued rather than as an actively marketed branded medicine. Discontinuation does not necessarily mean the product was withdrawn for safety or efficacy reasons. For OVCON-35, the commercial explanation is consistent with product lifecycle management and generic competition.

The Orange Book is relevant for determining listed patents and generic certification history. OVCON-35 no longer has a commercially meaningful exclusivity position. Any historical Orange Book patents would not prevent current generic availability after their expiration or delisting.

Regulatory issue	OVCON-35 assessment
Current branded marketing	No longer commercially active
FDA safety withdrawal	No established safety withdrawal basis
Generic availability	Yes, through equivalent norethindrone/ethinyl estradiol products
Active brand exclusivity	None of commercial significance
Orange Book relevance	Historical patent and exclusivity analysis
Paragraph IV exposure	Primarily historical, associated with generic approval timing

Sources include FDA Drugs@FDA records, the Orange Book, and product labeling databases.[1-3]

How many patents covered OVCON-35?

The commercially relevant protection for OVCON-35 was limited compared with newer pharmaceutical products. Combination oral contraceptives generally depend on formulation, dosage, manufacturing, and regulatory exclusivity rather than a large portfolio of high-value composition-of-matter patents.

The likely protection structure included:

1. Product formulation or dosage-form claims
2. Chewable-tablet manufacturing claims
3. Combination or regimen claims
4. Method-of-use claims for contraception
5. Regulatory exclusivity associated with the original NDA

These categories rarely create a durable barrier after generic approval unless the formulation has a technically difficult delivery system or a clinically differentiated release profile. OVCON-35's chewable tablet was commercially distinctive but did not create a high barrier comparable with an extended-release drug, injectable product, inhaled medicine, or biologic.

No active patent estate currently supports a branded OVCON-35 revenue stream. Generic manufacturers were able to market equivalent products after satisfying FDA abbreviated approval requirements.

What formulations are protected by OVCON-35 patents?

The formulation distinction was the chewable dosage form containing norethindrone and ethinyl estradiol. The formulation addressed administration convenience rather than a novel active ingredient or complex delivery technology.

A generic manufacturer seeking approval had to demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. The generic product did not need to reproduce every inactive ingredient, color, flavor, or commercial presentation, provided that it met FDA requirements and did not infringe enforceable patent claims.

The chewable format created limited commercial differentiation because:

• The active ingredients were long-established.
• The dose was conventional.
• The product did not use a biologic manufacturing process.
• The formulation did not require specialized injection or device technology.
• Patients and pharmacies had lower switching costs than in specialty-drug markets.

What Paragraph IV challenges affected OVCON-35?

Generic applicants may file Paragraph IV certifications when they assert that listed patents are invalid, unenforceable, or not infringed. Historical generic approval activity for OVCON-35 would have been the principal source of any Paragraph IV litigation risk.

The commercial importance of a Paragraph IV challenge depends on whether the brand can obtain a 30-month stay, whether the listed patent is enforceable, and whether the generic applicant launches at risk. For a mature oral contraceptive, litigation value generally declines as:

• More generic applicants enter.
• The product's annual revenue falls.
• Alternative contraceptive products expand.
• The remaining patent term shortens.
• Payers favor generic substitution.

There is no current evidence of an active, commercially material OVCON-35 Paragraph IV dispute. Historical litigation, if any, would need to be evaluated against FDA ANDA records and federal court dockets rather than current product sales data.

How did OVCON-35 compare with competing contraceptive products?

OVCON-35 competed in a market where the active ingredients were widely available in multiple strengths and dosage forms.

Product or category	Active ingredients	Differentiation	Competitive position
OVCON-35	Norethindrone/ethinyl estradiol	Chewable tablet	Brand product with limited post-generic durability
Generic norethindrone/ethinyl estradiol	Same active ingredients	Lower price	Primary substitute
Femcon Fe-type products	Norethindrone/ethinyl estradiol plus iron	Chewable format and iron tablets	Competing branded or generic option
Levonorgestrel/ethinyl estradiol products	Different progestin	Broad availability and low cost	Major therapeutic substitute
Desogestrel/ethinyl estradiol products	Different progestin	Alternative tolerability profile	Segment competitor
Drospirenone/ethinyl estradiol products	Different progestin	Differentiated clinical positioning	Higher-value branded and generic segment
Long-acting reversible contraception	Intrauterine or implant products	Extended duration	Structural substitute for daily pills

OVCON-35 lacked the clinical or delivery-system differentiation that supported premium pricing in some competing products. Its most defensible feature was the chewable format, but that attribute was insufficient to sustain brand pricing after generic competition.

What was the financial trajectory of OVCON-35?

Warner Chilcott did not generally report OVCON-35 revenue as a separately disclosed major product line in public filings. The company reported product and segment performance at a broader level, limiting the ability to calculate a verified annual revenue series for OVCON-35 alone.[4]

The financial trajectory can nevertheless be established directionally:

Branded growth phase

OVCON-35 generated branded revenue while Warner Chilcott controlled the product and before generic substitution became commercially significant. Revenue depended on prescription volume, payer coverage, physician promotion, and the product's chewable positioning.

Generic erosion phase

Generic entry compressed net sales through lower prices and reduced prescription share. The erosion would have affected both volume and realized price:

• Volume moved to generic equivalents.
• Pharmacy substitution reduced patient choice at the point of dispensing.
• Payers reduced reimbursement for the branded product.
• Promotional investment became less economically rational.
• Gross profit declined as fixed commercial costs were spread over fewer prescriptions.

Discontinuation phase

Once branded revenue fell below the level needed to justify manufacturing, inventory, regulatory maintenance, and commercialization, discontinuation became economically rational. The product's discontinuation removed the brand from the active revenue base, while generic manufacturers continued to serve residual demand.

No reliable public filing supports a current standalone revenue estimate for OVCON-35. Any precise revenue figure would be speculative.

What licensing deals affected OVCON-35?

No major current licensing transaction is publicly associated with OVCON-35. The product changed corporate ownership through broader pharmaceutical acquisitions rather than through a widely reported asset-specific licensing deal.

The relevant ownership sequence was:

Period	Corporate event
Original commercial period	Warner Chilcott marketed the product
2013	Actavis acquired Warner Chilcott
2015	Actavis acquired Allergan and adopted the Allergan name
2020	AbbVie acquired Allergan

These transactions transferred product rights within larger portfolios. They did not create a new exclusivity position for OVCON-35.

What patent litigation affects OVCON-35 today?

No active, high-value patent litigation is known to affect the current OVCON-35 market. The brand is discontinued, generic products are available, and the underlying active ingredients are long established.

The principal present-day legal risks are generic-manufacturer risks involving:

• Labeling compliance
• Product quality
• Manufacturing deviations
• Trademark or trade-dress claims
• Distribution and supply agreements
• State substitution requirements

These issues are distinct from the patent litigation that typically surrounds a newly launched branded drug.

What generic entry risks remain?

Generic entry risk is no longer a future event for OVCON-35. It has already occurred. The relevant business question is the level of competition among generic suppliers.

Generic-market risks include:

• Price compression from multiple suppliers
• API procurement constraints
• Manufacturing-site concentration
• FDA warning letters or remediation
• Periodic supply shortages
• Low margins that discourage redundant capacity
• Substitution by other contraceptive formulations

Because norethindrone and ethinyl estradiol are established ingredients, the principal barrier is reliable manufacturing rather than patent ownership. A supplier with an approved chewable product can compete on price, distribution, and supply reliability.

What is the competitive and commercial outlook?

OVCON-35 has no meaningful standalone commercial growth outlook as a branded product. The relevant market is the broader generic oral-contraceptive segment.

Demand for oral contraception remains substantial, but market share is distributed across multiple progestin-estrogen combinations, generic manufacturers, retail channels, telehealth providers, and long-acting contraceptive products. The original OVCON-35 brand is unlikely to regain material share without a new owner, relaunch strategy, or clinically meaningful reformulation.

For generic manufacturers, the opportunity is stable but low-margin. A chewable norethindrone/ethinyl estradiol product can retain demand among patients who prefer chewable administration, but it competes against lower-priced conventional tablets and other contraceptive methods.

How strong is the OVCON-35 patent estate?

The current patent estate is commercially weak. The product has no active branded exclusivity that supports premium pricing, no complex biologic manufacturing barrier, and no apparent device or delivery system that prevents substitution.

Patent-strength factor	Assessment
Composition-of-matter protection	Weak or expired
Formulation protection	Limited practical value
Method-of-use protection	Limited because contraception is an established indication
Manufacturing complexity	Low to moderate
Generic substitution barrier	Low
Current litigation leverage	Minimal
Revenue protection	None of material significance

Key Takeaways

• OVCON-35 was a chewable norethindrone 0.4 mg and ethinyl estradiol 0.035 mg oral contraceptive.
• Warner Chilcott was the original commercial owner; the product later moved through Actavis, Allergan, and AbbVie corporate ownership.
• Generic competition eliminated the brand's pricing power and led to commercial discontinuation.
• Current market value resides in generic equivalents, not in the OVCON-35 brand.
• No active patent or Orange Book exclusivity position has meaningful commercial significance today.
• No current high-value Paragraph IV or patent litigation materially affects the product.
• Public company filings do not provide a reliable standalone OVCON-35 revenue series.
• The remaining business risks are manufacturing, supply, quality, and generic price competition.

FAQs

Is OVCON-35 still available from pharmacies?

The branded OVCON-35 product is discontinued. Generic norethindrone/ethinyl estradiol chewable products may be available depending on supplier, pharmacy inventory, and market status.

Is OVCON-35 the same as Femcon Fe?

The products are closely related but should not be treated as identical in every presentation. OVCON-35 contains norethindrone and ethinyl estradiol in a chewable formulation. Femcon Fe-type products may include iron tablets and different packaging or labeling.

Did AbbVie report OVCON-35 sales separately?

No reliable public AbbVie filing provides a separately reported current OVCON-35 revenue figure. Product revenue was incorporated into broader portfolio reporting and became immaterial after discontinuation.

Can a generic manufacturer relaunch the OVCON-35 brand?

A manufacturer could seek commercial rights to the trademark or launch an equivalent product under a new label, subject to FDA approval, manufacturing requirements, trademark rights, and market economics. Relaunching the original brand would not restore expired patent exclusivity.

Does OVCON-35 have biosimilar risk?

No. OVCON-35 is a small-molecule oral contraceptive, not a biologic. The relevant competitive threat is generic substitution through the ANDA pathway, not biosimilar approval.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: OVCON-35, NDA 020685.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. DailyMed. (n.d.). Norethindrone and ethinyl estradiol chewable tablets prescribing information. National Library of Medicine.
4. Warner Chilcott Limited. (2012). Annual report and Form 10-K filings.
5. Actavis, Inc. (2013). Annual report and Form 10-K filings.